Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

ARS Pharmaceuticals (SPRY) Receivables - Net (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Receivables - Net for 2 consecutive years, with $25.3 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 210.06% to $25.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Dec 2025, up 210.06% year-over-year, with the annual reading at $25.3 million for FY2025, 210.06% up from the prior year.
  • Receivables - Net hit $25.3 million in Q4 2025 for ARS Pharmaceuticals, down from $36.5 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $36.5 million in Q3 2025 to a low of $773000.0 in Q3 2024.